Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)

Posted on by

-Trial-in-Progress poster provides overview on PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic HNSCC- LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 /PRNewswire/ –…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.